Review
doi: 10.2174/156802607781696819.
A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development
Affiliations
- PMID: 17692029
- DOI: 10.2174/156802607781696819
Item in Clipboard
Review
A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development
Curr Top Med Chem.
2007.
Abstract
This manuscript describes a comparison of the physicochemical properties of marketed oral drugs with those of 45 structurally confirmed orally bioavailable anti-cancer protein kinase inhibitors currently in different phases of clinical development. It is evident from the data presented that these kinase inhibitors are on average larger (over 110 Da), more lipophilic (over 1.5 log units) and more complex (approximately two more rotatable bonds) than those of marketed oral drugs. In contrast, hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) counts are not significantly different.
Similar articles
-
A comparison of physiochemical property profiles of development and marketed oral drugs.J Med Chem. 2003 Mar 27;46(7):1250-6. doi: 10.1021/jm021053p. J Med Chem. 2003. PMID: 12646035
-
Molecular inflation, attrition and the rule of five.Adv Drug Deliv Rev. 2016 Jun 1;101:22-33. doi: 10.1016/j.addr.2016.01.018. Epub 2016 Feb 1. Adv Drug Deliv Rev. 2016. PMID: 26836397 Review.
-
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10. J Med Chem. 2012. PMID: 22734674
-
Time-related differences in the physical property profiles of oral drugs.J Med Chem. 2004 Dec 2;47(25):6338-48. doi: 10.1021/jm049717d. J Med Chem. 2004. PMID: 15566303
-
Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.J Med Chem. 2019 Feb 28;62(4):1701-1714. doi: 10.1021/acs.jmedchem.8b00686. Epub 2018 Sep 27. J Med Chem. 2019. PMID: 30212196 Review.
Cited by
-
Chiral kinase inhibitors.Curr Top Med Chem. 2011;11(7):800-9. doi: 10.2174/156802611795165052. Curr Top Med Chem. 2011. PMID: 21291394 Free PMC article. Review.
-
A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.Molecules. 2021 Dec 5;26(23):7376. doi: 10.3390/molecules26237376. Molecules. 2021. PMID: 34885957 Free PMC article. Review.
-
The rise of fragment-based drug discovery.Nat Chem. 2009 Jun;1(3):187-92. doi: 10.1038/nchem.217. Nat Chem. 2009. PMID: 21378847 Review.
-
The influence of the 'organizational factor' on compound quality in drug discovery.Nat Rev Drug Discov. 2011 Sep 30;10(10):749-65. doi: 10.1038/nrd3552. Nat Rev Drug Discov. 2011. PMID: 21959288 Review.
-
Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies.Onco Targets Ther. 2022 May 2;15:479-495. doi: 10.2147/OTT.S357765. eCollection 2022. Onco Targets Ther. 2022. PMID: 35535170 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
